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Abstract
Background
Multiple Chemical Sensitivity (MCS) is a chronic condition characterized by reports of recur-
rent symptoms in response to low level exposure to various chemical substances. Recent
findings suggests that dysregulation of the immune system may play a role in MCS
pathophysiology.
Objectives
The aim of this study was to examine baseline and low dose n-butanol-induced upper air-
way inflammatory response profiles in MCS subjects versus healthy controls.
Method
Eighteen participants with MCS and 18 age- and sex-matched healthy controls were
enrolled in the study. Epithelial lining fluid was collected from the nasal cavity at three time
points: baseline, within 15 minutes after being exposed to 3.7 ppm n-butanol in an exposure
chamber and four hours after exposure termination. A total of 19 cytokines and chemokines
were quantified. Furthermore, at baseline and during the exposure session, participants
rated the perceived intensity, valence and levels of symptoms and autonomic recordings
were obtained.
Results
The physiological and psychophysical measurements during the n-butanol exposure ses-
sion verified a specific response in MCS individuals only. However, MCS subjects and
healthy controls displayed similar upper airway inflammatory mediator profiles (P>0.05) at
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baseline. Likewise, direct comparison of mediator levels in the MCS group and controls
after n-butanol exposure revealed no significant group differences.
Conclusion
We demonstrate no abnormal upper airway inflammatory mediator levels in MCS subjects
before or after a symptom-eliciting exposure to low dose n-butanol, implying that upper air-
ways of MCS subjects are functionally intact at the level of cytokine and chemokine produc-
tion and secretory capacity. This suggests that previous findings of increased cytokine
plasma levels in MCS are unlikely to be caused by systemic priming via excessive upper air-
way inflammatory processes.
Introduction
A substantial proportion of the adult population report different degrees of chemical intoler-
ances towards everyday chemicals, e.g. fragranced consumer products, car exhaust, pesticides
and new furniture’s at concentrations usually considered to be harmless [1]. The estimated
prevalence varies substantially but in about 0.5% to 6.3% of the population [2–4,4–8], expo-
sures to everyday chemicals elicit a complex array of symptoms at a much greater magnitude
and often with disabling consequences in the form of social and occupational lifestyle changes
and reduction in life quality [9,10]. Multiple chemical sensitivity (MCS) is a common term
used to describe this severe form of chemical intolerance [11,12].
Controversially, no dose-response relationship has been identified linking exposure concen-
tration to the symptom magnitude in MCS [13] and the type and severity of reported symp-
toms to an exposure are highly variable. Symptoms from the central nervous system (CNS)
conveyed by migraine headaches, dizziness, extreme fatigue, and concentration difficulties are
common, often combined with non-specific symptoms from other organ systems such as the
mucosa/respiratory tract, musculoskeletal system and/or the gastro-intestinal tract [8,11,13].
Both physiological and psychological processes have been suggested as underlying mecha-
nisms in MCS, but no definit conclusions can be drawn from available studies at this point.
Dysregulation of the immune system and/or neurogenic inflammation is frequently proposed
as mechanisms likely to play a role in the disease aetiology [14–21] and it has thus been sug-
gested that immunological mediators might play a role in linking the immune and neural sys-
tems in these disorders, thereby playing a pivotal role in symptom elicitation [20,22–24].
Recently, altered levels of immunological mediators such as cytokines, chemokines and growth
factors have been reported in blood plasma from subjects with MCS in two independent studies
[14,20], however, the mechanism (s) or event(s) responsible for the abnormal mediator levels
are unknown. It has been implied that MCS, at least partly, is a respiratory-based disorder
involving excessive activation of the immune system in the upper airways, possibly due to
induction of non-specific immune responses in the respiratory mucosa to low levels of irritants
(airborne chemicals, particles or infectious agents) [15,25,26]. Immunological mediators
secreted into the respiratory mucosa could subsequently be transferred directly into peripheral
circulation affecting the mediator profile in the peripheral blood. Alternatively, is it possible
that local inflammation in the upper airways can stimulate release of inflammatory mediators
at a secondary location if sensory impulses from the original site of inflammation are being
rerouted via the central nervous system, thereby causing neurogenic inflammation at a distant
tissue site [21,27]. Evidence supporting this chain of events was provided by Kimata (2004)
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reporting increased plasma levels of inflammatory biomarkers in MCS subjects immediately
after being exposed to a symptom eliciting mixture of volatile organic compounds while resid-
ing in a room that had recently been painted [28].
With focus on the inflammatory environment in the upper respiratory system, the aim of
this study was to compare levels of inflammatory mediators at baseline in subjects with MCS
versus an age- and gender-matched healthy control group and sequentially examine if exposure
to low concentrations of the odorant n-butanol would convey a different upper airway inflam-
matory response in MCS subjects. In the attempt to mimic an authentic everyday experience
described by subjects with MCS, the exposure was carried-out in an exposure chamber with
full-body exposure. The inflammatory environment in the upper airways was monitored before
and twice after the exposure session by measuring levels of selected cytokines and chemokines
with different effector functions.
Material and Methods
Study population
Participants suffering fromMCS and healthy controls were recruited through advertisement at
public places and in a local Swedish newspaper. Exclusion criteria for participants of both
groups included smoking, pregnancy, current breast feeding and doctor’s diagnosed fibromyal-
gia, chronic fatigue or irritable bowel syndrome. An additional exclusion criteria included
anosmia and all participants were prior to the exposure screened for this condition using a
0.44% v/v (336 ppm) concentration of n-butanol (99%, Merck) of the Connecticut Chemosen-
sory Clinical Research Center Threshold Test [29].
A total of 36 subjects who considered themselves especially sensitive were contacted by
phone and pre-screened for eligibility using the US Consensus Criteria for MCS and the revi-
sions suggested by Lacour et al. [11,12], which were operationalized as follows: 1) symptoms
for at least 6 months; 2) symptoms occur in response to exposure to low-levels of chemicals
that do not induce symptoms in other subjects who are exposed to the same levels; 3) symp-
toms occur when exposed and lessen or resolve when the symptom-triggering exposure is
removed; 4) symptoms are elicited by at least two unrelated chemical substances; 5) presence
of at least one symptom from the CNS (e.g. headache, fatigue, dizziness, memory problems,
concentration difficulties or tiredness) and one symptom from another organ system; 6) symp-
toms cause significant impairment in daily life, either in social, recreational, occupational, edu-
cational, or economic situations (confirmed by the Chemical Sensitivity Scale-score in
Table 1). A total of 18 subjects (16 women, 2 men) fulfilled the MCS criteria and were included
in the study. Eighteen subjects (14 women, 4 men) were recruited as age- and sex-matched
healthy controls. The controls did not fulfill any of the study criteria for MCS, and reported no
avoidance behavior, annoyance or symptoms attributed to low-level chemical exposure. None
of the participants in the control group shared housing with an MCS affected individual or had
any close relative, i.e. parent, grandparent, sibling or child with MCS.
Demographic information and self-reported problems
Prior to exposure, background characteristics in terms of sex, age, morbidities, smoking or use
of snuff were collected from all study participants and they were asked to fill in the following
questionnaire instruments: (1) the Chemical Sensitivity Scale [30] to assess affective and behav-
ioral reactions to everyday chemical exposure; (2) the anxiety, depression and somatization
subscales of the Symptom Checklist-90 (SCL-90) inventory (Fridell et al., 2002; Derogatis et al.,
1976); (3) the Perceived Stress Scale [31,32] to assess current levels of perceived stress; (4) the
Airway Inflammatory Profiling in Multiple Chemical Sensitivity
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Somatosensory Amplification Scale [33] to assess to what degree respondents are bothered by
uncomfortable visceral and somatic sensations.
Exposure chamber and exposure procedure
Participants were exposed to n-butanol (99.4% J.T. Baker) while seated in a windowed expo-
sure chamber. The exposure chamber had a volume of 2.7 m3 (height: 200 cm, width: 90 cm,
depth: 150 cm) and the exposure concentration of n-butanol was 11.5 mg/m3 (3.7 ppm). The
procedure is described in more details in Andersson et al. 2013 and Andersson et al. 2015. The
odorant n-butanol was chosen for the exposure procedure based on a pilot test in which MCS
sufferers judged the compound to be symptom-eliciting and because it had been used success-
fully in previous challenge studies [34,35].The concentration of n-butanol was clearly detect-
able (above the olfactory threshold 0.012mg/m3; [36]), but well below its threshold for sensory
irritation (75mg/m3; [37]).
Unknown to the participants, no odorant was delivered into the exposure chamber during
the first 10 minutes of testing. After this initial period of blank exposure, n-butanol was
released into the chamber and reached its peak concentration about 8 minutes later, as depicted
in Fig 1. The concentration remained at this peak level for the rest of the session (42 minutes).
The temperature and relative humidity inside the chamber was continuously monitored during
Table 1. Characteristics of the multiple chemical sensitivity (MCS) and the control group. Symptom Checklist (SCL).
MCS group (n = 18) Control group (n = 18) P-value1
Sex male/female, n 2/16 4/14
Age mean (±SD) 44 (14) 41 (14) .562
Chemical Sensitivity Scale mean (±SD) 96 (16) 72 (10) < .001
Perceived Stress Scale, mean (±SD) 18 (6) 16 (8) .522
SCL-90 Anxiety, mean (±SD) 0.5 (0.5) 0.5 (0.6) .710
SCL-90 Depression, mean (±SD) 0.7 (0.6) 0.6 (0.7) .743
SCL-90 Somatization, mean (±SD) 0.8 (0.6) 0.4 (0.4) .016
Somatosensory Ampliﬁcation Scale, mean (±SD) 29 (7) 25 (6) .078
1p-values refer to results of Mann-Whitney U-test.
doi:10.1371/journal.pone.0143534.t001
Fig 1. Overview of the exposure procedure and samples collection.During the first 10 min of testing, no odorant was delivered to the chamber, where
after n-butanol was released into the chamber and reached its peak concentration about 8 min later. The concentration remained at this peak level (3.7 ppm)
for the rest of the exposure session. Airway epithelial lining fluid was collected within 30 minutes prior to the exposure session (time point 1, TP1), within 15
minutes post exposure session (TP2) and again 4 hours after the exposure session was terminated (TP3).
doi:10.1371/journal.pone.0143534.g001
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the exposures and the mean temperature was 22°C (±1°C) and the relative humidity was 16%
(± 2%) [38].
At baseline and at regular intervals during the exposure session, the participants rated the
perceived intensity and valence as well as the levels of possible symptoms. Additionally, auto-
nomic recordings of the breathing rate, tonic electrodermal activity, pulse rate and pulse rate
variability were obtained at baseline and periodically during the exposure. A detailed descrip-
tion of the methodology used for collection of self-reported ratings and autonomic recordings
has been published separately in Andersson et al. (2015), verifying the experimental setups
ability to elicit characteristic MCS symptoms in the MCS group and to produce the expected
group differences [38].
Sample collection
Airway epithelial lining fluid was collected within 30 minutes prior to the exposure session
(time point 1, TP1), within 15 minutes post exposure session (TP2) and again 4 hours after the
exposure session had been terminated (TP3) as outlined in Fig 1. The participants could choose
themselves where to stay and what to do during the period between TP2 and TP3. Sample
material was collected using a recently introduced method that is non-invasive, easy manage-
able and highly sensitive [39]. Strips of 5 x 30mm filter paper were inserted gently by means of
direct vision into the nasal cavity, laterally against the anterior part of the inferior turbinate.
After insertion, a nasal clip was applied and the strips were left for absorption for 2 minutes
[39–41]. Next, the strips were removed, placed in an Eppendorph tube and immediately stored
at -80°C until analysis. Sample material was collected from both nostrils simultaneously. The
filter material is composed of an absorptive synthetic hydroxylated polyester medium (Accu-
wik Ultra, fibrous hydroxylatedpolyester sheets, cat. no.SPR0730; Pall Life Sciences, Ports-
mouth, Hampshire, UK) optimized for collection, storage and conjugated release of sample
material, and have successfully been utilized in studies with protein containing samples such as
epithelial lining fluid [39–41].
Approval
All research reported here was approved by the Umeå Regional Ethics Board, Sweden (Dnr 2013-
19-31) and conducted in accordance with the Helsinki Declaration. All participants were given
written and verbal information about the study, and signed informed consent was obtained from
all study participants. All participants were given 500 SEK (~50 EUR) for their participation.
Protein isolation
Total protein fractions were extracted from the filter papers by submerging the strips from
each nostril into the cup of a cellulose acetate tube filter (0.22 μm pore size) within an Eppen-
dorf tube (Spin-X Centrifuge Tube Filter, Sigma-Aldrich, Cat no.CLS8161), and applying 300
uL of Milliplex Assay Buffer (Millipore, Cat no. L-AB) added with 1x complete protease inhibi-
tor cocktail (Roche Applied Science, Indianapolis, IN). The moist filter papers and assay buffer
were then centrifuged for 5 minutes in a cooled centrifuge at 16000g. The tube containing
extracted proteins from epithelial lining fluid was stored at -80°C until analysis.
Quantification of cytokines and chemokines in epithelial lining fluid
We selected 19 cytokines and chemokines to represent inflammatory mediators associated with
different type of immune responses. For simplicity, we grouped these mediators into categories
representing type-1 (Th1/CD8+/NK cells/innate lymphoid cells (ILC), type-2 (Th2, eosinophils,
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ILC2), type-17 (Th17, neutrophils, ILC17), regulatory type (Treg) responses or lymphocyte acti-
vation properties based on the current perception on which cell types that produce the given
mediators and/or are mainly affected by these mediators. Levels of the 19 immune mediators
were measured in duplicates in the eluted samples using the Multi-Spot Human TH1/TH2
10-Plex Cytokine Assay System [interferon-γ (IFN-γ), interleukin-1β (IL-1β), IL-2, IL-4, IL-5,
Chemokine (C-X-Cmotif) ligand 8 (CXCL8) /IL-8, IL-10, IL-12p70, IL-13 and tumor necrosis
factor-α (TFN-α)], the Multi-Spot Human Chemokine 9-plex Assay System [CCL11/eotaxin-1,
Chemokine (C-Cmotif) ligand 4 (CCL4)/macrophage inflammatory protein-1β, CCL26/
eotaxin-3, CCL17/thymus activation-regulated chemokine, CXCL10/IFN-inducible protein-10,
CXCL8/IL8, CCL2/monocyte chemotactic protein-1 (MCP-1), CCL22/ macrophage-derived
chemokine and CCL13/MCP-4] and Human IL-17A Singleplex Assay (Meso Scale Discovery,
Gaithersburg, MD). Plates were read at a Sector Imager 2400A (Meso Scale Discovery). The
lower limit of detection for each mediator can be found in S1 Table.
Total protein quantification
Total amount of protein in the eluted epithelial lining fluid was measured using the Qubit1
Protein Assay Kits and a Qubit1 2.0 Fluorometer according to the manufacturer. Total pro-
tein concentrations in the 108 samples (36 x 3 TP) ranged from 3.20 to 4.98 mg/mL and cyto-
kine and chemokine levels were normalized according to the total protein concentration in the
samples as pg analyte/mg total protein.
Statistical analyses
The SPSS 19.0 software package was used for statistical analysis; the level of significance was
set at 0.05. Descriptive statistics for the two groups were generated and significant group differ-
ences were identified using independent samples t-tests. Untransformed as well as transformed
cytokine and chemokine levels were examined for a normal distribution using a Shapiro-Wilk
test and by visual inspection of histograms. Most variables showing a slightly skewed distribu-
tion continued to be skewed after log transformation, and all statistical analysis was carried out
on the untransformed data.
Differences in cytokine and chemokine concentrations between the MCS group and the
control group were examined using Mann–Whitney U test with the 19 cytokine and chemo-
kine measurements as the dependent variables and the grouping variable, i.e. MCS or control,
as the explanatory variable. A secondary outcome measure was differences over time within
the MCS or the control group comparing mediator levels between the three TP´s. This test was
performed using an independent-sample Kruskal–Wallis one-way analysis of variance with the
19 mediator measurements as the dependent variables and the three TP´s for collection of epi-
thelial lining fluid as the explanatory variables. When statistically significant, Dunn's multiple
comparisons procedure and Bonferroni correction was used to determine pairwise differences.
Principal component analysis (PCA) was performed on combined normalized cytokine and
chemokine values at TP1 using the software package Latentix 2.12 (www.latentix.com), and
scores for principal component (PC) 1 and 2 were plotted against each other to detect com-
bined immunological cytokine patterns in the dataset.
Results
Participant characteristics
Characteristics of the MCS and healthy control groups are shown in Table 1. A total of 36 sub-
jects participated in the study; 18 fulfilling the criteria for MCS and 18 enrolled as healthy
Airway Inflammatory Profiling in Multiple Chemical Sensitivity
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controls. Mean age was comparable between the two groups, while more women than men par-
ticipated in the study. Compared to the controls, the MCS group showed a significantly higher
score on the Chemical Sensitivity Scale (P< .001) and on the somatization subscale of the
SCL-90 (P< .05). The MCS group also reported higher numbers of morbidities other than
MCS [38]. No other significant demographic group differences were found.
Soluble immune mediators within upper airways
Epithelial lining fluid was successfully collected from all 36 participants at the three sampling
time points (Fig 1), and cytokine and chemokine levels were quantified in a total of 108 sam-
ples. To ascertain that data were not influenced by unexpected dilution due to differences in
levels of secreted fluid volumes, we adjusted all immune mediator data based on the individual
total protein content (ng/mL) per TP. The median concentration and interquartile range (IQR)
measured are presented in Table 2 for each cytokine and chemokine at TP1, TP2 and TP3. The
number and percentages of samples with cytokine or chemokine concentrations below limit of
detection are presented in S1 Table.
Baseline levels of upper airway mediators
One primary objective was to identify differences in cytokine/chemokine regulation in upper
airways between the MCS and the control group at baseline. However, no statistically signifi-
cant group differences were identified in upper airway mediator levels at TP1 for any of the 19
mediators included (Fig 2). Moreover, using a multivariate principal component analysis to
explore if the pattern of inflammatory markers differed in MCS as opposed to controls, we
found no statistically significant differences (S2 Fig).
Upper airway response profiles to n-butanol exposure
MCS subjects perceived the n-butanol exposure as being more intense, more unpleasant and
rated symptoms to be of greater magnitude compared to controls as reported in Andersson
et al. (2015) [38]. Here we examined if the difference in symptom elicitation was associated
with in situ changes in the release of upper airway inflammatory mediators. A direct compari-
son of mediator levels measured at TP2 and TP3 was performed between the two groups, since
the similar baseline levels between MCS subjects and controls allowed for a direct comparison
without prior adjustment. We identified no significant differences for any of the 19 cytokine
and chemokines upon n-butanol exposure (Table 2). Median values with IQR for cytokines
IFN-γ, TNF-α, IL-1β and IL-4 at each TP are presented in Fig 3 and similar data for the
remaining 15 mediators are shown in S1 Fig.
Time-course changes
The repeated sampling of epithelial lining fluid at the three consecutive time points allowed for
analyses of time-course differences in MCS and controls. The comparison revealed several
time-dependent changes in mediator concentrations (Fig 3, S1 Fig and Table 2). For IFN-γ, IL-
4, CCL22 and CCL26, concentrations decreased significantly at TP3 compared to TP1 and TP2
in both groups. For IL-1β, the analysis showed a significantly higher level at TP1 compared to
TP2 and TP3 in the control group but not in the MCS group. However, altogether we found no
apparent group differences in secretion of immune mediators in upper airway epithelial lining
fluid over the course of the study.
Airway Inflammatory Profiling in Multiple Chemical Sensitivity
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Discussion
We examined whether local upper airway inflammatory responses were excessively activated
in MCS subjects, thereby playing a role in symptom elicitation. A broad panel of 19 representa-
tive pro- and anti-inflammatory cyto- and chemokines were selected to be measured in situ
within upper airways of MCS subjects and healthy controls at baseline and after a controlled
low-dose n-butanol exposure shown to elicit symptoms in MCS subjects only [38]. Our data
demonstrated no abnormal inflammatory mediator levels in the upper airways at any time
point in MCS subjects. These findings suggest that upper airways of MCS subjects are function-
ally intact at the level of inflammatory mediator responsiveness and release.
The demographic data showed that the MCS group scored higher on the Chemical Sensitiv-
ity Scale suggesting that the case criteria for inclusion in the study were successful. As presented
by Andersson et al. (2015), over the course of the exposure, the MCS group perceived the n-
butanol exposure as being more intense, more unpleasant and rated symptoms to be of greater
magnitude compared to controls [38]. Additionally, individuals with MCS had higher than
normal pulse rate and lower than normal pulse rate variability [38], indicating abnormal regu-
lation of the sympathetic branch of the autonomic nervous system during the exposure [42].
Accumulated, these findings verify the ability of the experimental setup to produce the
expected symptom elicitation in MCS while not in healthy controls, and therefore provided a
reliable platform for the upper airway immunological comparisons presented herein.
Immunological mediator profiles were assessed at baseline in both unexposed airways of
asymptomatic MCS subjects and controls and in exposed airways from the same individuals.
Table 2. Quantified levels of immunemediators in epithelial lining fluid of upper airways. Median level with interquartile range of each mediator (in pg
analyte/mg total protein) measured in the upper airway epithelial lining fluid from the MCS group and from the control group at the three time points (TP); TP1
at zero hours, TP2 at the end of exposure and TP3 4 hours post exposure session. Asterisks refer to significant differences (P 0.05) in analyte concentra-
tion between TP1, TP2 and TP3 within either the MCS or the control group identified using an Kruskal-Wallis test and Dunn's (1964) procedure with a Bonfer-
roni correction for multiple comparisons as post-hoc analysis. CCL = Chemokine (C-C motif) ligand, IL = interleukin, IFN-γ = interferon-γ; TNF-α = tumor
necrosis factor-α. The immunological mediators are sorted according to whether they are mainly represented in type-1 responses, type-2 responses, type-17
responses or involved in immune regulation (Reg) or activation (Act).
MCS group (n = 18) Control group (n = 18)
TP1 TP2 TP3 TP1 TP2 TP3
Type 1 IFN-γ 4.48 (2.01–6.85) 4.72 (1.87–6.63) 1.93 (0.70–3.11)* 3.93 (3.13–7.63) 4.63 (1.68–6.23) 2.19 (0.70–3.07)*
IL-12p70 8.16 (6.00–19.10) 3.82 (0.82–10.84) 4.12 (0.62–16.73) 8.53 (5.09–15.83) 5.07 (2.45–19.12) 4.46 (1.97–9.92)
CXCL10 4957 (2255–8405) 2942 (1350–6853) 5752 (3497–9911) 5778 (2325–7123) 5469 (1318–7815) 3913 (1931–5796)
TNF-α 83.03 (32.50–221.3) 60.09 (23.30–132.9) 42.93 (14.77–212.5) 82.65 (44.23–231.8) 47.94 (18.40–132.6) 63.62 (21.05–104.1)
CCL2 567.6 (337.8–567.6) 423.8 (220.2–752.5) 604.8 (324.3–1045) 358.6 (274.7–751.1) 437.3 (187.7–640.6) 316.5 (238.5–748.4)
CCL4 228.0 (82.65–472.5) 169.7 (75.33–276.9) 112.7 (44.41–332.1) 205.8 (135.9–387.6) 182.2 (105.4–282.1) 143.6 (85.6–248.2)
Type 2 IL-4 1.98 (0.34–4.15) 1.99 (0.85–3.33) 0.003 (0.002–0.89)* 1.51 (055–4.31) 1.48 (0.85–2.56) 0.003 (0.003–24.02)*
IL-5 11.23 (4.51–20.48) 4.7 (2.99–15.2) 5.40 (3.32–13.4) 8.43 (3.77–19.53) 10.13 (2.80–18.71) 5.30 (2.62–12.39)
IL-13 95.56 (47.75–185.4) 74.54 (21.98–127.6) 40.59 (24.79–182.8) 98.36 (51.72–161.1) 61.91 (31.51–110.8) 49.15 (17.36–125.1)
CCL11 607.3 (310.3–1047) 525.7 (224.1–867.8) 621.9 (313.5–1064) 522.4 (361.4–1108) 535.5 (254.7–840.4) 376.8 (180.0–974.7)
CCL13 47.98 (37.30–57.73) 42.69 (29.01–59.87) 29.86 (16.21–51.17) 38.74 (31.09–53.03) 42.03 (28.66–51.27) 32.24 (22.16–48.12)
CCL17 31.26 (17.25–49.97) 28.62 (16.3–33.94) 25.63 (16.87–60.30) 26.95 (12.53–51.68) 28.30 (13.37–49.18) 18.11 (12.0–35.76)
CCL22 953.0 (724–1262) 955.8 (761.1–1202) 513.8 (94.66–1031)* 949.8 (855.5–1068) 998.0 (791.4–1205) 701.5 (410.6–969.9)*
CCL26 71.84 (43.02–123.5) 81.11 (40.47–104.2) 0.07 (0.06–75.16)* 73.10 (36.56–133.5) 85.11 (43.08–183.9) 0.07 (0.06–24.02)*
Type 17 IL-1β 132.4 (52.35–318.7) 73.05 (29.30–116.3) 70.08 (26.61–157.9) 222.7 (90.45–322.4)* 83.05 (38.24–122.2) 76.45 (49.07–125.0)
IL-17A 0.51 (0.25–2.37) 0.35 (0.02–1.35) 0.37 (0.02–1.36) 1.88 (0.15–3.07) 0.49 (0.05–3.01) 1.20 (0.24–2.85)
CXCL8 9835 (5268–14773) 6450 (2926–10199) 6085 (1899–9418) 7880 (4747–14866) 6699 (2732–8407) 5159 (3858–7529)
Reg. IL-10 31.95 (19.34–49.73) 30.77 (11.98–56.25) 16.09 (10.23–41.10) 28.29 (13.85–42.33) 21.00 (12.56–31.68) 16.70 (12.51–29.05)
Act. IL-2 123.2 (63.94–182.5) 55.78 (28.63–87.73) 49.25 (15.91–125.3) 88.50 (37.52–176.18) 48.83 (19.62–140.4) 33.68 (16.84–89.45)
doi:10.1371/journal.pone.0143534.t002
Airway Inflammatory Profiling in Multiple Chemical Sensitivity
PLOS ONE | DOI:10.1371/journal.pone.0143534 November 23, 2015 8 / 15
This study design made it possible to compare and infer systematic changes within the individ-
ual’s secretory capacity, as well as within the MCS and control group, providing an ideal com-
parative platform for detection of MCS-associated inflammatory regulation of in situ upper
airway responses to the exposure.
Before initiating the study we made the assumption that for airway inflammation to be
involved in the systemic fast response observed after chemical exposure in MCS subjects, any
effector molecules of disease relevance would have to been synthesized, i.e. available, prior to or
at the time for symptom elicitation. This is important as the normal protein processing machin-
ery takes around 5–6 hours from cellular activation to synthesis and secretion of new proteins
after activation of epithelial and immune cells, while symptom elicitation inMCS subjects most
often takes place within minutes to an hour after contact with environmental triggering agents
[43]. The reported instant chemically-induced response in MCS subjects was also apparent in the
current study where the MCS group differed significantly (p< .001) from the control group on
symptoms ratings after just 30 minutes exposure [38]. Based on this assumed necessity of imme-
diate availability of inflammatory mediators in order to convey disease symptoms, we decided to
collect all repeated samples within a short time frame after n-butanol exposure, and conse-
quently, any changes in mediator levels over time would have to be due to secretion of already
synthesized and constitutively deregulated levels of mediators from activated effector cells.
Our finding of similar cytokine and chemokine profiles in unexposed (baseline) upper air-
ways of MCS and healthy individuals suggests that no abnormal inflammation or immune reg-
ulation is taking place in the upper airway of the MCS subjects during normal unexposed
conditions. Moreover, our observation of similar cytokine and chemokine levels in upper air-
ways of MCS subjects and controls after low-dose n-butanol exposure, despite MCS subjects
experiencing a deviating reaction to the exposure session, implies that symptom elicitation in
Fig 2. Ratios of upper airways inflammatory mediators in unexposedMCS versus healthy controls.Data represent ratios of medians with 95%
confidence interval between cytokine and chemokine levels in the upper airway epithelial lining fluid in MCS subjects and healthy controls. CCL = Chemokine
(C-C motif) ligand, IL = interleukin, IFN-γ = interferon-γ; TNF-α = tumor necrosis factor-α. The immunological mediators are sorted according to whether they
are mainly represented in type-1 responses, type-2 responses, type-17 responses or involved in immune regulation (Reg) or activation (Act).
doi:10.1371/journal.pone.0143534.g002
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Fig 3. n-butanol exposure and upper airway inflammatory mediators. Data are shown as median level with interquartile range of interferon-γ (IFN-γ),
tumor necrosis factor-α (TNF-α), Interleukin-4 (IL-4) and IL-1β (in pg analyte/mg total protein) measured in the upper airway epithelial lining fluid from the
MCS group and from the control group at the three time points (TP); TP1 at time zero, TP2 at the end of the n-butanol exposure and TP3 4 hours post
exposure. Asterisks refer to significant differences (P 0.05) in analyte concentrations between TP1, TP2 and TP3 within either the MCS or the control
group.
doi:10.1371/journal.pone.0143534.g003
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MCS takes place without localized secretion of immunological mediators from epithelial and
immune cells in the upper airways. Likewise, our finding underpins that previous reports of
elevated cytokine levels within circulating blood [14,20] is without involvement of upper air-
way inflammatory mediators being secreted and transferred into peripheral circulation.
Although noMCS-associated airway inflammatory responses could be linked to the exposure
session, the time-course analysis revealed changes in mediator levels over time with IFN-γ, IL-4,
CCL22 and CCL26 levels decreasing statistically significantly at TP3 compared to the earlier TP’s
in both MCS and controls. For IL-1β, the data showed a significantly increased level at TP1 com-
pared to TP2 and TP3 in the control group, with the same tendency for MCS. Since these time-
dependent changes are not exclusive to one of the groups, we interpret that it cannot be linked to
MCS, but might be attributed to a common regulatory mechanism, possibly as a result of a non-
MCS associated response to the exposure chamber conditions. Alternatively, it could be a conse-
quence of a methodically introduced dilution factor caused by repeated sampling with three sam-
ples collected within a five hours period. This phenomenon has been reported for sampling of
epithelial lining fluid using nasal lavage, where it is recommended only to collect one sample
daily [44]. However, we found no changes in the total level of protein (approx. 360 ug/mL protein
per sample) at any time point, why the drop in some mediators from TP1 to TP3 seems unlikely
to be due to an overall methodically introduced dilution factor. Rather it could relate to the short
interval between sampling points, simply not allowing for re-synthesis of some cytokines and
chemokines that therefore diminish due to low level secretion.
For this study we utilized a newly implemented filter paper-based method for collection of
epithelial lining fluid onto an absorbent matrix introduced by Chawes et al. (2010) [39]. This
method has the advantage that epithelial lining fluid is collected without disturbing the epithe-
lial cell layer and without introducing a considerable and variable dilution factor [39], which is
often the case using nasal lavage [45–48]. We found that this technique was easily imple-
mented, inexpensive and provided reliable data, and except from a minor tickling sensation
while having the filter pieces inserted, the participants reported no discomfort, hence making
the technique ideal for repeated sampling of epithelial lining fluid. Moreover we decided to
measure and adjust for total protein concentration with the epithelial lining fluid per individual
at all TPs. This decision was made in order to account for possible inter-individual differences
in fluid secretion capacities (e.g. due to runny nose).
It is a limitation of the study that the number of enrolled participants in each group is rela-
tively low; however, 36 subjects was the number of participants that could be systematically
handled within this study design of repeated measures and controlled n-butanol exposure.
Symptomatic heterogeneity among the MCS individuals is a recurrent challenge for all clinical
research within MCS, and although the inclusion criteria appears to be adequate based on
group response [38] and MCS group characteristics, it is a possible that the experimental setup
is unable to reveal group differences because of the relatively low number of participants and
the considerable variation in response patterns observed between MCS subjects. However,
since the variation within the healthy control group was observed to be at similar levels, it is
less likely that heterogeneity within the MCS group is the direct cause of the study outcome.
It would also have strengthened the study if we had included a blank exposure sample in a
blinded setup. This way it would have been possible to determine whether any immunological
changes were purely a result of biological interactions between the exposure and responding
cell types in upper airways, or if psychological mechanisms, like a stress response and the antic-
ipated discomfort would have contributed to or been the principal mechanism responsible for
the changes. Unfortunately, due to the design of the exposure chamber, it was not possible to
perform dual exposures, and to collect epithelial lining fluid continuously during the course of
the exposure. Furthermore, the aim of this study was to reveal if the exposure session would
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trigger differential secretion of immunological mediators in the upper airway of MCS subjects
and not necessarily to identify any underlying causes of differences at this present stage.
Conclusion
In conclusion, the results from this study suggests that a MCS symptom-eliciting exposure
using a low dose of the odorant n-butanol does not trigger a local inflammatory response in
upper airways based on cytokine and chemokine profiles. The systemic response to the expo-
sure including differences in chemosensory perception is thereof suggested not to be initiated
or influenced by upper airway inflammation. Based on these findings, it seems unlikely that the
previously reported alterations in blood plasma cytokine levels in unexposed MCS subjects is
caused by exaggerated upper airway inflammatory responses.
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